From the claim on the label to the grade behind it.
A brand owner writes the words that end up on the shelf. This order puts the grade vocabulary first, then the record your claims will be measured against, then the tools for taking a label apart before a regulator or a buyer does.
7 pages, in the order that makes the next one easier.
A path is a reading order, not a course. Each step is a page that already exists, with one line on why it comes where it does. Read them in sequence and the self-check at the end should hold no surprises.
How we grade
Every page after this one uses the same six rungs and two off-ladder states. Ten minutes here and no chip on the site will surprise you.
Page 1 of 7The shelf says, the record says
Fourteen label lines set beside the trial record, each with its grade. Find the one you have seen.
Page 2 of 7The CBG condition dossiers
Ten questions people ask about CBG, each with the studies named, what they tested, and the grade the registry gives. Your claims will be read against these.
Page 3 of 7The gap map
What has been studied, what has not, and what would need to happen before a grade could move. The empty rows stay in plain view.
Page 4 of 7Full-spectrum, broad-spectrum, isolate
The three terms describe composition. Rank them by how well they work and an unproven claim walks straight back onto the label.
Page 5 of 7Label lab
Type a label claim and see which kind it is, whether it carries a hedge, and what grade the record behind it holds.
Page 6 of 7What a buyer checks
Three checks a careful buyer runs on your product before the jar is opened. Pass them and the claims question mostly answers itself.
Page 7 of 7
5 questions, each answered somewhere on the path.
Pick one option per question and press Check. Every correct answer is a fact the site documents, and the feedback links to the page that documents it. Checking runs in your browser; nothing is scored, stored or sent anywhere.
The other three orders.
Formulator · Lab or QA manager · Buyer, consumer or retail. Or start from how we grade, the page every path shares.
The blood-pressure note that appears on CBG pages is mechanistic and safety-relevant, not a benefit claim. CBG shows potent α2-adrenoceptor agonism in vitro, and α2 agonists can lower blood pressure — but no study has measured an actual blood-pressure effect of CBG. If you take blood-pressure medication or have a cardiovascular condition, consult a clinician first.
A learning path orders pages; it does not advise. Nothing on it is a claim that any product does anything for any disease. If you have experienced a possible adverse effect from a cannabinoid product, use the Report a safety event path. Peregrine Biopharma funds the platform and holds no editorial authority.